HealthcareServices

Global Cardiac Amyloidosis Market Analysis 2025–2029: Opportunities for Strategic Growth

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Cardiac Amyloidosis Market Size Likely To Evolve From 2025 Through 2034?

The cardiac amyloidosis market has demonstrated robust expansion over recent years. Its valuation is projected to climb from $5.26 billion in 2024 to $5.73 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.9%. This historical surge in growth can be linked to the escalating incidence of amyloidosis-related conditions, an increase in genetic mutations, enhanced awareness, a higher prevalence of transthyretin amyloidosis cases, and an expanding geriatric population.

The market for cardiac amyloidosis is projected to experience robust expansion in the coming years. This market is set to reach a value of $8.03 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this growth during the forecast period include enhanced diagnosis rates, governmental backing and initiatives, a rise in the prevalence of genetic mutations, and various patient assistance programs. Key trends anticipated in this timeframe involve the introduction of new treatments like vulrisiran, an increase in gene therapy research, an emphasis on precision medicine, improvements in diagnostic technologies, and the creation of innovative therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp

Which Drivers Are Impacting The Cardiac Amyloidosis Market?

The expanding geriatric population is anticipated to drive the future growth of the cardiac amyloidosis market. This demographic refers to older individuals, typically aged 65 and above, who often require specialized healthcare and support due to age-related changes. The increase in the geriatric population results from factors such as rising life expectancy, advancements in healthcare, and declining birth rates. A growing number of older adults elevates the prevalence of cardiac amyloidosis, as aging is a significant risk factor for amyloid protein accumulation in the heart. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the increasing geriatric population will propel the cardiac amyloidosis market.

What Are The Major Segment Categories Driving The Cardiac Amyloidosis Market Growth?

The cardiac amyloidosismarket covered in this report is segmented –

1) By Product Type: Light Chain Amyloidosis; Transthyretin Amyloidosis

2) By Treatment: Chemotherapy; Surgery; Supportive Care; Stem Cell Transplant; Targeted Therapy

3) By End-User: Hospitals; Ambulatory Surgical Centres; Clinics

Subsegments:

1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis; Primary Light Chain Amyloidosis; Secondary Light Chain Amyloidosis

2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm); Wild-type Transthyretin Amyloidosis (ATTRwt)

Which Competitive Trends Are Defining The Cardiac Amyloidosis Market Structure?

Major companies within the cardiac amyloidosis market are concentrating on technological innovations, including artificial intelligence (AI)-based software-only diagnostic tools, to improve early detection and patient clinical outcomes for this underdiagnosed disease. An artificial intelligence (AI)-powered, software-exclusive medical device for identifying cardiac amyloidosis functions as a diagnostic tool that employs artificial intelligence to examine echocardiographic images and pinpoint disease indicators without requiring additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology firm, received FDA clearance for EchoGo Amyloidosis, an AI-driven clinical instrument for the early detection of cardiac amyloidosis. This device is the first within the FDA’s Total Product Lifecycle Advisory Program (TAP) to be granted marketing authorization. By using artificial intelligence, EchoGo Amyloidosis analyzes echocardiograms to detect the disease from a single clip, thus addressing the urgent need for an earlier diagnosis before it advances unnoticed.

Which Industry Leaders Are Driving Innovation Across The Cardiac Amyloidosis Market?

Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., Eidos Therapeutics.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

How Do Regional Market Performances Compare Within The Cardiac Amyloidosis Industry?

North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cardiac Amyloidosis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21128&type=smp

Browse Through More Reports Similar to the Global Cardiac Amyloidosis Market 2025, By The Business Research Company

Cardiac Pacemakers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report

Cardiac Valve Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-valve-global-market-report

Cardiac Arrhythmia Monitoring Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-arrhythmia-monitoring-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795